Glioblastoma is a highly aggressive primary brain tumour with limited treatment options. Dysregulation of the phosphoinositide 3-kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR) signalling ...

Nab-paclitaxel and gemcitabine for the treatment of pancreatic adenocarcinoma at an academic center. This is an ASCO Meeting Abstract from the 2015 ASCO Annual Meeting I. This abstract does not ...

REVTORPYK is the first and only FDA-approved therapy that inhibits all class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2In ...

Women diagnosed with HR-positive, HER2-negative advanced breast cancer who lack a specific genetic mutation gained a new ...

Celcuity has won FDA approval for gedatolisib – its first product – as a treatment for patients with a particular form of ...

Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple-negative breast cancer: A phase III study. This is an ASCO Meeting Abstract from the 2015 ASCO ...

Metabolism has always been a crucial pillar in cancer treatment, but clinical considerations have been limited to general diet and nutrition advice, minimizing the potential therapeutic impact of ...

Gedatolisib is the first approved agent to inhibit class I PI3K isoforms plus both mTOR complexes, addressing a long-standing challenge in comprehensive PI3K/AKT/mTOR pathway blockade. The indication ...

The PI3K/Akt pathway was thought to be confined to membranes. "These results also have critical implications for cancer treatment," Cryns says. Current treatments that target PI3K may not work because ...

The FDA approved the PI3K/AKT/mTOR inhibitor Revtorpyk with fulvestrant and with or without Pfizer's CDK4/6 Ibrance based on Phase III data.